KLP Kapitalforvaltning AS Acquires New Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

KLP Kapitalforvaltning AS bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, HoldingsChannel.com reports. The firm bought 407,059 shares of the company’s stock, valued at approximately $8,972,000.

Several other large investors also recently bought and sold shares of TEVA. Stifel Financial Corp raised its stake in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after buying an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after acquiring an additional 33,277 shares during the last quarter. Thrivent Financial for Lutherans grew its position in shares of Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,218 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $24,314,000. Finally, Pinnbrook Capital Management LP purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $4,966,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.5 %

Shares of NYSE:TEVA opened at $16.18 on Tuesday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a market cap of $18.34 billion, a price-to-earnings ratio of -11.16, a PEG ratio of 1.44 and a beta of 0.82. The stock’s 50-day moving average price is $17.70 and its two-hundred day moving average price is $18.19. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TEVA. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Bank of America decreased their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, March 19th. Finally, Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.